GlassScriptPhysician profile
Joe K Ahn
NPI 1750557310
$4,194.50
in general payments reported to CMS, 2019-2025
33 companies · $790 in 2025
The $790 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $337 · 2021: $335 · 2022: $452 · 2023: $812 · 2024: $1,089 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,690.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $449.12 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $356.65 | 2019-2025 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $342.48 | 2020-2025 | Wainua, Farxiga |
| Abbott Laboratories | $300.13 | 2023-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Jot Dx, Tendril |
| Janssen Pharmaceuticals, INC | $285.83 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.91 | 2020-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $240.77 | 2019-2025 | |
| Esperion Therapeutics, INC. | $223.85 | 2024-2025 | Nexletol, Nexlizet |
| Amgen INC. | $212.61 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $205.91 | 2020-2025 | |
| Abiomed | $160.64 | 2023-2025 | Impella |
| Amarin Pharma, INC. | $160.00 | 2019-2022 | |
| Boston Scientific Corporation | $136.27 | 2019-2024 | Watchman Flx |
| Merck Sharp & Dohme LLC | $134.51 | 2021-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.61 | 2020-2025 | Lifevest |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $69.62 | 2021-2024 | Azure Xt Dr Mri Surescan |
| Cvrx, INC. | $69.46 | 2024-2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $64.27 | 2023-2025 | Onpattro |
| Impulse Dynamics (USA) INC. | $51.61 | 2023-2025 | Optimizer, Optimizer |
| Lexicon Pharmaceuticals, INC. | $51.33 | 2023-2024 | Inpefa |
| Biosense Webster, INC. | $41.62 | 2024 | Carto 3 |
| Sanofi-Aventis U.S. LLC | $39.00 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $31.01 | 2024 | Arcalyst |
| Bard Peripheral Vascular, INC. | $30.57 | 2024 | Venclose Maven Catheter |
| Regeneron Healthcare Solutions, INC. | $28.50 | 2019 | |
| Scpharmaceuticals INC. | $25.57 | 2025 | |
| Atricure, INC. | $21.46 | 2024 | |
| Heartflow, INC. | $21.09 | 2025 | |
| Novo Nordisk INC | $19.17 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $17.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.38 | 2024 | Livalo |
| Csl Behring | $14.35 | 2024 | Kcentra |
| Azurity Pharmaceuticals, INC. | $13.20 | 2024 | Edarbi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Ahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.